Similarly, in another trial of six PDAC patients, intravenous delivery of anti-mesothelin CAR T-cells resulted in stable disease, with progression-free survival (PFS) times of 3.8 and 5.4 months in two patients, respectively, and no adverse complications associated with off-tumor toxicities. The gene discussed is MSLN; the disease is neoplasm.